Document:

<PAGE>

                                                                   EXHIBIT 10.12
                            INDEMNIFICATION AGREEMENT

      THIS AGREEMENT (the "Agreement") is made effective as of ______________
__, 2004 by and between Adeza Biomedical Corporation, a Delaware corporation
(the "Company") and __________ ("Indemnitee").

                                WITNESSETH THAT:

      WHEREAS, Indemnitee performs a valuable service for the Company; and

      WHEREAS, the Board of Directors of the Company have adopted Bylaws (the
"Bylaws") providing for the indemnification of directors of the Company to the
maximum extent authorized by Section 145 of the Delaware General Corporation
Law, as amended (the "Law"); and

      WHEREAS, the Bylaws and the Law, by their nonexclusive nature, permit
contracts between the Company and the officers and directors of the Company with
respect to indemnification of such officers and directors; and

      WHEREAS, in accordance with the authorization as provided by the Law, the
Company may purchase and maintain a policy or policies of director's and
officer's liability insurance ("D&O Insurance"), covering certain liabilities
which may be incurred by its officers or directors in the performance of their
obligations to the Company; and

      WHEREAS, as a result of recent developments affecting the terms, scope and
availability of D&O Insurance there exists general uncertainty as to the extent
of protection afforded Company officers and directors by such D&O Insurance and
said uncertainty also exists under statutory and bylaw indemnification
provisions; and

      WHEREAS, in recognition of past services and in order to induce Indemnitee
to continue to serve as an officer or director of the Company, the Company has
determined and agreed to enter into this contract with Indemnitee;

      NOW, THEREFORE, in consideration of Indemnitee's continued service as an
officer or director after the date hereof, the parties hereto agree as follows:

      1.    INDEMNITY OF INDEMNITEE. The Company hereby agrees to hold harmless
and indemnify Indemnitee to the fullest extent authorized or permitted by the
provisions of the Law, as such may be amended from time to time, and Article
VII, Section 6 of the Bylaws, as such may be amended. In furtherance of the
foregoing indemnification, and without limiting the generality thereof:

            (a)   Proceeding, Other Than Proceedings by or in the Right of the
Company. Indemnitee shall be entitled to the rights of indemnification provided
in this Section 1(a) if, by reason of his Corporate Status (as defined in
Section 13 below), he is,

<PAGE>

or is threatened to be made, a party to or participant in any Proceeding (as
defined in Section 13 below) other than a Proceeding by or in the right of the
Company. Pursuant to this Section 1(a), Indemnitee shall be indemnified against
all Expenses (as defined in Section 13 below), judgments, penalties, fines and
amounts paid in settlement actually and reasonably incurred by him or on his
behalf in connection with such Proceeding or any claim, issue or matter therein,
if he acted in good faith and in a manner he reasonably believed to be in or not
opposed to the best interests of the Company and, with respect to any criminal
Proceeding, had no reasonable cause to believe his conduct was unlawful.

            (b)   Proceedings by or in the Right of the Company. Indemnitee
shall be entitled to the rights of indemnification provided in this Section 1(b)
if, by reason of his Corporate Status, he is, or is threatened to be made, a
party to or participant in any Proceeding brought by or in the right of the
Company to procure a judgment in its favor. Pursuant to this Section 1(b),
Indemnitee shall be indemnified against all Expenses actually and reasonably
incurred by him or on his behalf in connection with such Proceeding if he acted
in good faith and in a manner he reasonably believed to be in or not opposed to
the best interests of the Company; provided, however, that if applicable law so
provides, no indemnification against such Expenses shall be made in respect of
any claim, issue or matter in such Proceeding as to which Indemnitee shall have
been adjudged to be liable to the Company, unless and to the extent that the
Court of Chancery of the State of Delaware shall determine that such
indemnification may be made.

            (c)   Indemnification for Expenses of a Party Who is Wholly or
Partly Successful. Notwithstanding any other provision of this Agreement, to the
extent that Indemnitee is, by reason of his Corporate Status, a party to and is
successful, on the merits or otherwise, in any Proceeding, he shall be
indemnified to the maximum extent permitted by law against all Expenses actually
and reasonably incurred by him or on his behalf in connection therewith. If
Indemnitee is not wholly successful in such Proceeding but is successful, on the
merits or otherwise, as to one or more but less than all claims, issues or
matters in such Proceeding, the Company shall indemnify Indemnitee against all
Expenses actually and reasonably incurred by him or on his behalf in connection
with each successfully resolved claim, issue or matter. For purposes of this
Section l(c) and without limitation, the termination of any claim, issue or
matter in such a Proceeding by dismissal, with or without prejudice, shall be
deemed to be a successful result as to such claim, issue or matter.

      2.    ADDITIONAL INDEMNITY. In addition to, and without regard to any
limitations on, the indemnification provided for in Section 1, the Company shall
and hereby does indemnify and hold harmless Indemnitee against all Expenses,
judgments, penalties, fines and amounts paid in settlement actually and
reasonably incurred by him or on his behalf if, by reason of his Corporate
Status he is, or is threatened to be made, a party to or participant in any
Proceeding (including a Proceeding by or in the right of the Company),
including, without limitation, all liability arising out of the negligence or
active or passive

                                       2
<PAGE>

wrongdoing of Indemnitee. The only limitation that shall exist upon the
Company's obligations pursuant to this Agreement shall be that the Company shall
not be obligated to make any payment to Indemnitee that is finally determined
(under the procedures, and subject to the presumptions, set forth in Sections 6
and 7 hereof) to be unlawful under Delaware law.

      3.    CONTRIBUTION IN THE EVENT OF JOINT LIABILITY.

            (a)   Whether or not the indemnification provided in Sections 1 and
2 hereof is available, in respect of any Proceeding in which the Company is
jointly liable with Indemnitee (or would be if joined in such Proceeding), the
Company shall pay, in the first instance, the entire amount of any judgment or
settlement of such Proceeding without requiring Indemnitee to contribute to such
payment and the Company hereby waives and relinquishes any right of contribution
it may have against Indemnitee. The Company shall not enter into any settlement
of any Proceeding in which the Company is jointly liable with Indemnitee (or
would be if joined in such Proceeding) unless such settlement provides for a
full and final release of all claims asserted against Indemnitee.

            (b)   Without diminishing or impairing the obligations of the
Company set forth in the preceding subparagraph, if, for any reason, Indemnitee
shall elect or be required to pay all or any portion of any judgment or
settlement in any Proceeding in which the Company is jointly liable with
Indemnitee (or would be if joined in such Proceeding), the Company shall
contribute to the amount of expenses (including attorneys' fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred and paid
or payable by Indemnitee in proportion to the relative benefits received by the
Company and all officers, directors or employees of the Company other than
Indemnitee who are jointly liable with Indemnitee (or would be if joined in such
Proceeding), on the one hand, and Indemnitee, on the other hand, from the
transaction from which such Proceeding arose; provided, however, that the
proportion determined on the basis of relative benefit may, to the extent
necessary to conform to law, be further adjusted by reference to the relative
fault of Company and all officers, directors or employees of the Company other
than Indemnitee who are jointly liable with Indemnitee (or would be if joined in
such Proceeding), on the one hand, and Indemnitee, on the other hand, in
connection with the events that resulted in such expenses, judgments, fines or
settlement amounts, as well as any other equitable considerations which the law
may require to be considered. The relative fault of the Company and all
officers, directors or employees of the Company other than Indemnitee who are
jointly liable with Indemnitee (or would be if joined in such Proceeding), on
the one hand, and Indemnitee, on the other hand, shall be determined by
reference to, among other things, the degree to which their actions were
motivated by intent to gain personal profit or advantage, the degree to which
their liability is primary or secondary, and the degree to which their conduct
is active or passive.

                                       3
<PAGE>

            (c)   The Company hereby agrees to fully indemnify and hold
Indemnitee harmless from any claims of contribution which may be brought by
officers, directors or employees of the Company other than Indemnitee who may be
jointly liable with Indemnitee.

      4.    INDEMNIFICATION FOR EXPENSES OF A WITNESS. Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee is, by reason of his
Corporate Status, a witness in any Proceeding to which Indemnitee is not a
party, he shall be indemnified against all Expenses actually and reasonably
incurred by him or on his behalf in connection therewith.

      5.    ADVANCEMENT OF EXPENSES. Notwithstanding any other provision of this
Agreement, the Company shall advance all reasonable Expenses incurred by or on
behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee's
Corporate Status within ten (10) days after the receipt by the Company of a
statement or statements from Indemnitee requesting such advance or advances from
time to time, whether prior to or after final disposition of such Proceeding.
Such statement or statements shall reasonably evidence the Expenses incurred by
Indemnitee and shall include or be preceded or accompanied by an undertaking by
or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately
be determined that Indemnitee is not entitled to be indemnified against such
Expenses. Any advances and undertakings to repay pursuant to this Section 5
shall be unsecured and interest free. Notwithstanding the foregoing, the
obligation of the Company to advance Expenses pursuant to this Section 5 shall
be subject to the condition that, if, when and to the extent that the Company
determines that Indemnitee would not be permitted to be indemnified under
applicable law, the Company shall be entitled to be reimbursed, within thirty
(30) days of such determination, by Indemnitee (who hereby agrees to reimburse
the Company) for all such amounts theretofore paid; provided, however, that if
Indemnitee has commenced or thereafter commences legal proceedings in a court of
competent jurisdiction to secure a determination that Indemnitee should be
indemnified under applicable law, any determination made by the Company that
Indemnitee would not be permitted to be indemnified under applicable law shall
not be binding and Indemnitee shall not be required to reimburse the Company for
any advance of Expenses until a final judicial determination is made with
respect thereto (as to which all rights of appeal therefrom have been exhausted
or lapsed).

      6.    PROCEDURES AND PRESUMPTIONS FOR DETERMINATION OF ENTITLEMENT TO
INDEMNIFICATION. It is the intent of this Agreement to secure for Indemnitee
rights of indemnity that are as favorable as may be permitted under the law and
public policy of the State of Delaware. Accordingly, the parties agree that the
following procedures and presumptions shall apply in the event of any question
as to whether Indemnitee is entitled to indemnification under this Agreement:

                                       4
<PAGE>

            (a)   To obtain indemnification (including, but not limited to, the
advancement of Expenses and contribution by the Company) under this Agreement,
Indemnitee shall submit to the Company a written request, including therein or
therewith such documentation and information as is reasonably available to
Indemnitee and is reasonably necessary to determine whether and to what extent
Indemnitee is entitled to indemnification. The Secretary of the Company shall,
promptly upon receipt of such a request for indemnification, advise the Board of
Directors in writing that Indemnitee has requested indemnification.

            (b)   Upon written request by Indemnitee for indemnification
pursuant to the first sentence of Section 6(a) hereof, a determination, if
required by applicable law, with respect to Indemnitee's entitlement thereto
shall be made in the specific case by one of the following three methods, which
shall be at the election of Indemnitee: (i) by a majority vote of the
Disinterested Directors (as defined in Section 13 below), even though less than
a quorum, or (ii) by Independent Counsel (as defined in Section 13 below) in a
written opinion, or (iii) by the stockholders.

            (c)   If the determination of entitlement to indemnification is to
be made by Independent Counsel pursuant to Section 6(b) hereof, the Independent
Counsel shall be selected as provided in this Section 6(c). The Independent
Counsel shall be selected by Indemnitee (unless Indemnitee shall request that
such selection be made by the Board of Directors). Indemnitee or the Company, as
the case may be, may, within ten (10) days after such written notice of
selection shall have been given, deliver to the Company or to Indemnitee, as the
case may be, a written objection to such selection; provided, however, that such
objection may be asserted only on the ground that the Independent Counsel so
selected does not meet the requirements of "Independent Counsel" set forth in
this Agreement, and the objection shall state with particularity the factual
basis of such assertion. Absent a proper and timely objection, the person so
selected shall act as Independent Counsel. If a written objection is made and
substantiated, the Independent Counsel selected may not serve as Independent
Counsel unless and until such objection is withdrawn or a court has determined
that such objection is without merit. If, within twenty (20) days after
submission by Indemnitee of a written request for indemnification pursuant to
Section 6(a) hereof, no Independent Counsel shall have been selected and not
objected to, either the Company or Indemnitee may petition the Court of Chancery
of the State of Delaware or other court of competent jurisdiction for resolution
of any objection which shall have been made by the Company or Indemnitee to the
other's selection of Independent Counsel and/or for the appointment as
Independent Counsel of a person selected by the court or by such other person as
the court shall designate, and the person with respect to whom all objections
are so resolved or the person so appointed shall act as Independent Counsel
under Section 6(b) hereof. The Company shall pay any and all reasonable fees and
expenses of Independent Counsel incurred by such Independent Counsel in
connection with acting pursuant to Section 6(b) hereof, and the Company

                                       5
<PAGE>

shall pay all reasonable fees and expenses incident to the procedures of this
Section 6(c), regardless of the manner in which such Independent Counsel was
selected or appointed.

            (d)   In making a determination with respect to entitlement to
indemnification hereunder, the person or persons or entity making such
determination shall presume that Indemnitee is entitled to indemnification under
this Agreement if Indemnitee has submitted a request for indemnification in
accordance with Section 6(a) of this Agreement. Anyone seeking to overcome this
presumption shall have the burden of proof and the burden of persuasion, by
clear and convincing evidence.

            (e)   Indemnitee shall be deemed to have acted in good faith if
Indemnitee's action is based on the records or books of account of the
Enterprise (as defined in Section 13 below), including financial statements, or
on information supplied to Indemnitee by the officers of the Enterprise in the
course of their duties, or on the advice of legal counsel for the Enterprise or
on information or records given or reports made to the Enterprise by an
independent certified public accountant or by an appraiser or other expert
selected with reasonable care by the Enterprise. In addition, the knowledge
and/or actions, or failure to act, of any director, officer, agent or employee
of the Enterprise shall not be imputed to Indemnitee for purposes of determining
the right to indemnification under this Agreement. Whether or not the foregoing
provisions of this Section 6(e) are satisfied, it shall in any event be presumed
that Indemnitee has at all times acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the
Company. Anyone seeking to overcome this presumption shall have the burden of
proof and the burden of persuasion, by clear and convincing evidence.

            (f)   The Company acknowledges that a settlement or other
disposition short of final judgment may be successful if it permits a party to
avoid expense, delay, distraction, disruption and uncertainty. In the event that
any Proceeding to which Indemnitee is a party is resolved in any manner other
than by adverse judgment against Indemnitee (including, without limitation,
settlement of such Proceeding with or without payment of money or other
consideration) it shall be presumed that Indemnitee has been successful on the
merits or otherwise in such Proceeding. Anyone seeking to overcome this
presumption shall have the burden of proof and the burden of persuasion, by
clear and convincing evidence.

            (g)   If the person, persons or entity empowered or selected under
Section 6(b) to determine whether Indemnitee is entitled to indemnification
shall not have made a determination within thirty (30) days after receipt by the
Company of the request therefor, the requisite determination of entitlement to
indemnification shall be deemed to have been made and Indemnitee shall be
entitled to such indemnification, absent (i) a misstatement by Indemnitee of a
material fact, or an omission of a material fact necessary to make Indemnitee's
statement not materially misleading, in connection with the request for
indemnification, or (ii) a prohibition of such indemnification under applicable
law; provided, however, that such thirty (30) day period may be extended for a
reasonable

                                       6
<PAGE>

time, not to exceed an additional fifteen (15) days, if the person, persons or
entity making the determination with respect to entitlement to indemnification
in good faith requires such additional time for the obtaining or evaluating
documentation and/or information relating thereto; and provided further, that
the foregoing provisions of this Section 6(g) shall not apply if the
determination of entitlement to indemnification is to be made by the
stockholders pursuant to Section 6(b) of this Agreement and if (A) within
fifteen (15) days after receipt by the Company of the request for such
determination the Board of Directors or the Disinterested Directors, if
appropriate, resolve to submit such determination to the stockholders for their
consideration at an annual meeting thereof to be held within seventy-five (75)
days after such receipt and such determination is made thereat, or (B) a special
meeting of stockholders is called within fifteen (15) days after such receipt
for the purpose of making such determination, such meeting is held for such
purpose within sixty (60) days after having been so called and such
determination is made thereat.

            (h)   Indemnitee shall cooperate with the person, persons or entity
making such determination with respect to Indemnitee's entitlement to
indemnification, including providing to such person, persons or entity upon
reasonable advance request any documentation or information which is not
privileged or otherwise protected from disclosure and which is reasonably
available to Indemnitee and reasonably necessary to such determination. Any
Independent Counsel, member of the Board of Directors, or stockholder of the
Company shall act reasonably and in good faith in making a determination under
the Agreement of the Indemnitee's entitlement to indemnification. Any costs or
expenses (including attorneys' fees and disbursements) incurred by Indemnitee in
so cooperating with the person, persons or entity making such determination
shall be borne by the Company (irrespective of the determination as to
Indemnitee's entitlement to indemnification) and the Company hereby indemnifies
and agrees to hold Indemnitee harmless therefrom.

      7.    REMEDIES OF INDEMNITEE.

            (a)   In the event that (i) a determination is made pursuant to
Section 6 of this Agreement that Indemnitee is not entitled to indemnification
under this Agreement, (ii) advancement of Expenses is not timely made pursuant
to Section 5 of this Agreement, (iii) no determination of entitlement to
indemnification shall have been made pursuant to Section 6(b) of this Agreement
within ninety (90) days after receipt by the Company of the request for
indemnification, (iv) payment of indemnification is not made pursuant to this
Agreement within ten (10) days after receipt by the Company of a written request
therefor, or (v) payment of indemnification is not made within ten (10) days
after a determination has been made that Indemnitee is entitled to
indemnification or such determination is deemed to have been made pursuant to
Section 6 of this Agreement, Indemnitee shall be entitled to an adjudication in
an appropriate court of the State of Delaware, or in any other court of
competent jurisdiction, of his entitlement to such

                                       7
<PAGE>

indemnification. Indemnitee shall commence such proceeding seeking an
adjudication within one hundred eighty (180) days following the date on which
Indemnitee first has the right to commence such proceeding pursuant to this
Section 7(a). The Company shall not oppose Indemnitee's right to seek any such
adjudication.

            (b)   In the event that a determination shall have been made
pursuant to Section 6(b) of this Agreement that Indemnitee is not entitled to
indemnification, any judicial proceeding commenced pursuant to this Section 7
shall be conducted in all respects as a de novo trial, on the merits, and
Indemnitee shall not be prejudiced by reason of that adverse determination.

            (c)   If a determination shall have been made pursuant to Section
6(b) of this Agreement that Indemnitee is entitled to indemnification, the
Company shall be bound by such determination in any judicial proceeding
commenced pursuant to this Section 7, absent a prohibition of such
indemnification under applicable law.

            (d)   In the event that Indemnitee, pursuant to this Section 7,
seeks a judicial adjudication of his rights under, or to recover damages for
breach of, this Agreement, or to recover under any D&O Insurance maintained by
the Company, the Company shall pay on his behalf, in advance, any and all
expenses (of the types described in the definition of Expenses in Section 13 of
this Agreement) actually and reasonably incurred by him in such judicial
adjudication, regardless of whether Indemnitee ultimately is determined to be
entitled to such indemnification, advancement of expenses or insurance recovery.

            (e)   The Company shall be precluded from asserting in any judicial
proceeding commenced pursuant to this Section 7 that the procedures and
presumptions of this Agreement are not valid, binding and enforceable and shall
stipulate in any such court that the Company is bound by all the provisions of
this Agreement.

      8.    NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION.

            (a)   The rights of indemnification as provided by this Agreement
shall not be deemed exclusive of any other rights to which Indemnitee may at any
time be entitled under applicable law, the certificate of incorporation of the
Company, the Bylaws, any agreement, a vote of stockholders or a resolution of
directors, or otherwise. No amendment, alteration or repeal of this Agreement or
of any provision hereof shall limit or restrict any right of Indemnitee under
this Agreement in respect of any action taken or omitted by such Indemnitee in
his Corporate Status prior to such amendment, alteration or repeal. To the
extent that a change in the Law, whether by statute or judicial decision,
permits greater indemnification than would be afforded currently under the
Bylaws and this Agreement, it is the intent of the parties hereto that
Indemnitee shall enjoy by this Agreement the greater benefits so afforded by
such change. No right or remedy herein conferred is intended to be exclusive of
any other right or remedy, and

                                       8
<PAGE>

every other right and remedy shall be cumulative and in addition to every other
right and remedy given hereunder or now or hereafter existing at law or in
equity or otherwise. The assertion or employment of any right or remedy
hereunder, or otherwise, shall not prevent the concurrent assertion or
employment of any other right or remedy.

            (b)   To the extent that the Company maintains an insurance policy
or policies providing liability insurance for directors, officers, employees, or
agents or fiduciaries of the Company or of any other corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise which such
person serves at the request of the Company, Indemnitee shall be covered by such
policy or policies in accordance with its or their terms to the maximum extent
of the coverage available for any such director, officer, employee or agent
under such policy or policies.

            (c)   In the event of any payment under this Agreement, the Company
shall be subrogated to the extent of such payment to all of the rights of
recovery of Indemnitee, who shall execute all papers required and take all
action necessary to secure such rights, including execution of such documents as
are necessary to enable the Company to bring suit to enforce such rights.

            (d)   The Company shall not be liable under this Agreement to make
any payment of amounts otherwise indemnifiable hereunder if and to the extent
that Indemnitee has otherwise actually received such payment under any insurance
policy, contract, agreement or otherwise.

      9.    EXCEPTION TO RIGHT OF INDEMNIFICATION. Notwithstanding any other
provision of this Agreement, Indemnitee shall not be entitled to indemnification
under this Agreement with respect to any Proceeding brought by Indemnitee, or
any claim therein, unless (i) the bringing of such Proceeding or making of such
claim shall have been approved by the Board of Directors or (ii) such Proceeding
is being brought by the Indemnitee to assert his rights under this Agreement.

      10.   DURATION OF AGREEMENT. All agreements and obligations of the Company
contained herein shall continue during the period Indemnitee is an officer or
director of the Company (or is or was serving at the request of the Company as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise) and shall continue thereafter so long as
Indemnitee shall be subject to any Proceeding (or any proceeding commenced under
Section 7 hereof) by reason of his Corporate Status, whether or not he is acting
or serving in any such capacity at the time any liability or expense is incurred
for which indemnification can be provided under this Agreement. This Agreement
shall be binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective successors (including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all or
substantially all of the business or assets of the Company), assigns, spouses,
heirs, executors and personal and legal representatives. This Agreement shall
continue in effect regardless of

                                       9
<PAGE>

whether Indemnitee continues to serve as an officer or director of the Company
or any other enterprise at the Company's request.

      11.   SECURITY. To the extent requested by Indemnitee and approved by the
Board of Directors, the Company may at any time and from time to time provide
security to Indemnitee for the Company's obligations hereunder through an
irrevocable bank line of credit, funded trust or other collateral. Any such
security, once provided to Indemnitee, may not be revoked or released without
the prior written consent of Indemnitee.

      12.   ENFORCEMENT.

            (a)   The Company expressly confirms and agrees that it has entered
into this Agreement and assumed the obligations imposed on it hereby in order to
induce Indemnitee to serve as an officer or director of the Company, and the
Company acknowledges that Indemnitee is relying upon this Agreement in serving
as an officer or director of the Company.

            (b)   This Agreement constitutes the entire agreement between the
parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the
parties hereto with respect to the subject matter hereof.

      13.   DEFINITIONS. For purposes of this Agreement:

            (a)   "Corporate Status" describes the status of a person who is or
was a director, officer, employee or agent or fiduciary of the Company or of any
other corporation, partnership, joint venture, trust, employee benefit plan or
other enterprise which such person is or was serving at the express written
request of the Company.

            (b)   "Disinterested Director" means a director of the Company who
is not and was not a party to the Proceeding in respect of which indemnification
is sought by Indemnitee.

            (c)   "Enterprise" shall mean the Company and any other corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise of
which Indemnitee is or was serving at the express written request of the Company
as a director, officer, employee, agent or fiduciary.

            (d)   "Expenses" shall include all reasonable attorneys' fees,
retainers, court costs, transcript costs, fees of experts, witness fees, travel
expenses, duplicating costs, printing and binding costs, telephone charges,
postage, delivery service fees and all other disbursements or expenses of the
types customarily incurred in connection with prosecuting, defending, preparing
to prosecute or defend, investigating, participating, or being or preparing to
be a witness in a Proceeding.

                                       10
<PAGE>

            (e)   "Independent Counsel" means a law firm, or a member of a law
firm, that is experienced in matters of corporation law and neither presently
is, nor in the past five (5) years has been, retained to represent: (i) the
Company or Indemnitee in any matter material to either such party (other than
with respect to matters concerning Indemnitee under this Agreement, or of other
indemnitees under similar indemnification agreements), or (ii) any other party
to the Proceeding giving rise to a claim for indemnification hereunder.
Notwithstanding the foregoing, the term "Independent Counsel" shall not include
any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Company
or Indemnitee in an action to determine Indemnitee's rights under this
Agreement. The Company agrees to pay the reasonable fees of the Independent
Counsel referred to above and to fully indemnify such counsel against any and
all Expenses, claims, liabilities and damages arising out of or relating to this
Agreement or its engagement pursuant hereto.

            (f)   "Proceeding" includes any threatened, pending or completed
action, suit, arbitration, alternate dispute resolution mechanism,
investigation, inquiry, administrative hearing or any other actual, threatened
or completed proceeding, whether brought by or in the right of the Company or
otherwise and whether civil, criminal, administrative or investigative, in which
Indemnitee was, is or will be involved as a party or otherwise, by reason of the
fact that Indemnitee is or was a director of the Company, by reason of any
action taken by him or of any inaction on his part while acting as an officer or
director of the Company, or by reason of the fact that he is or was serving at
the request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise; in each case
whether or not he is acting or serving in any such capacity at the time any
liability or expense is incurred for which indemnification can be provided under
this Agreement; including one pending on or before the date of this Agreement;
and excluding one initiated by an Indemnitee pursuant to Section 7 of this
Agreement to enforce his rights under this Agreement.

      14.   SEVERABILITY. If any provision or provisions of this Agreement shall
be held by a court of competent jurisdiction to be invalid, void, illegal or
otherwise unenforceable for any reason whatsoever: (i) the validity, legality
and enforceability of the remaining provisions of this Agreement (including
without limitation, each portion of any section of this Agreement containing any
such provision held to be invalid, illegal or unenforceable, that is not itself
invalid, illegal or unenforceable) shall not in any way be affected or impaired
thereby and shall remain enforceable to the fullest extent permitted by law; and
(ii) to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of any section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that
is not itself invalid, illegal or unenforceable) shall be construed so as to
give effect to the intent manifested thereby.

                                       11
<PAGE>

      15.   MODIFICATION AND WAIVER. No supplement, modification, termination or
amendment of this Agreement shall be binding unless executed in writing by both
of the parties hereto. No waiver of any of the provisions of this Agreement
shall be deemed or shall constitute a waiver of any other provisions hereof
(whether or not similar) nor shall such waiver constitute a continuing waiver.

      16.   NOTICE BY INDEMNITEE. Indemnitee agrees promptly to notify the
Company in writing upon being served with any summons, citation, subpoena,
complaint, indictment, information or other document relating to any Proceeding
or matter which may be subject to indemnification covered hereunder. The failure
to so notify the Company shall not relieve the Company of any obligation which
it may have to the Indemnitee under this Agreement or otherwise.

      17.   NOTICES. All notices, requests, demands and other communications
hereunder shall be in writing and shall be deemed to have been duly given if (i)
delivered by hand and receipted for by the party to whom said notice or other
communication shall have been directed, or (ii) mailed by certified or
registered mail with postage prepaid, on the third business day after the date
on which it is so mailed:

      (a)   If to Indemnitee, to the address set forth below Indemnitee
signature hereto.

      (b)   If to the Company, to:

            Adeza Biomedical Corporation
            1240 Elko Drive
            Sunnyvale, CA 94089
            Attention: Chief Executive Officer

or to such other address as may have been furnished to Indemnitee by the Company
or to the Company by Indemnitee, as the case may be.

      18.   IDENTICAL COUNTERPARTS. This Agreement may be executed in one or
more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute one and the same Agreement.
Only one such counterpart signed by the party against whom enforceability is
sought needs to be produced to evidence the existence of this Agreement.

      19.   HEADINGS. The headings of the paragraphs of this Agreement are
inserted for convenience only and shall not be deemed to constitute part of this
Agreement or to affect the construction thereof.

      20.   GOVERNING LAW. The parties agree that this Agreement shall be
governed by, and construed and enforced in accordance with, the laws of the
State of Delaware without application of the conflict of laws principles
thereof.

                                       12
<PAGE>

      21.   GENDER. Use of the masculine pronoun shall be deemed to include
usage of the feminine pronoun where appropriate.

      IN WITNESS WHEREOF, the parties hereto have executed this Indemnification
Agreement on and as of the day and year first above written.

                             ADEZA BIOMEDICAL CORPORATION

                             By:_______________________________________
                                   Emory V. Anderson
                                   President and Chief Executive Officer

                              _____________________________________, Indemnitee

                             Address:

                             1240 Elko Drive
                             Sunnyvale, CA 94089

                                       13<PAGE>
                                                                   EXHIBIT 10.13

                                                CONFIDENTIAL TREATMENT REQUESTED

                                    AGREEMENT

This AGREEMENT is made on the 24th day of December 1998

BETWEEN

UNILEVER PLC, an English company having its principal place of business at
Unilever House, Blackfriars, London EC4P 4BQ, England and UNILEVER NV, a
Netherlands company having its principal place of business at Weena 455, 3013 AL
Rotterdam, Netherlands (hereinafter collectively "Unilever"),

AND

ADEZA BIOMEDICAL Corporation, a Delaware, United States of America company,
having its principal place of business at 1240 Elko Drive, Sunnyvale, California
94089 (hereinafter "Licensee").

1.    DEFINITIONS

1.1   "Patent Rights" shall mean the patents and patent applications listed in
      attached Exhibit 1, any pending or granted counterparts claiming priority
      thereof, or claiming the same priorities as the patents and patent
      applications listed in attached Exhibit 1 filed anywhere throughout the
      world, and any continuations, continuations in part, divisions, reissues
      or reexaminations of the foregoing.

1.2   "Territory" shall mean all those territories where there are subsisting
      Patent Rights.

1.3   "Licensed Product" shall mean any device for qualitative or quantitative
      detection of the analytes specified in Appendix 2a covered by or made in
      accordance with, or adapted for use within a claim of a patent or
      published patent application within the Patent Rights.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

1.4   "Products Under Option" shall mean any device for qualitative or
      quantitative detection of the analytes specified in Appendix 2b covered by
      or made in Appendix 2b covered by or made in accordance with, or adapted
      for use within a claim of a patent or published patent applications with
      the Patent Rights.

1.5   "Net Sales" shall mean the amount invoiced by the Licensee or an Affiliate
      upon arms-length sale to an independent third party of Licensed Product or
      Products Under Option less any customary trade, quantity or cash discounts
      and non-affiliated broker's or agent's commissions actually allowed and
      taken, amounts repaid or credited by reason of rebate, rejection, return,
      short-dating or outdating, and less any import, value added or excise
      taxes and customs duties levied and any other governmental charges made as
      to production, sale, transportation, delivery or use to the extent such
      charges are paid by the Licensee or Affiliate and are separately
      identified on invoices.

1.6   "Effective Date" shall mean the date first above written.

1.7   "Calendar Half-year" shall mean the respective six month periods ending on
      the last business days of June and December respectively.

1.8   "Affiliate" in relation to the Licensee shall mean any company of which
      Licensee owns or controls a majority of the ordinary share capital.

2.    LICENCE GRANT

2.1   Unilever hereby grants to the Licensee and the Licensee hereby accepts
      with effect from the Effective Date a non-exclusive royalty-bearing
      licence under the Patent Rights in the Territory to make, use and sell
      Licensed Products.

2.2   Unilever hereby grants to the Licensee and the Licensee hereby accepts
      with effect from the Effective Date a non-exclusive option to a
      royalty-bearing licence to make, use and sell Products Under Option. This
      option may be exercised on a

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      per analyte basis at any time within the two (2) year period subsequent to
      the Effective Date of the Agreement, whereupon it will cease on a per
      analyte basis.

2.3   It is hereby expressly agreed that no licence is granted under any other
      Unilever patent rights whatsoever and no licence is granted for any
      analyte other than those under Appendix 2a and Appendix 2b, should the
      licence option be exercised.

2.4   There will be no right to sub-licence without prior written consent of
      Unilever.

2.5   The licence to the Licensee shall not be assigned or otherwise transferred
      in whole or in part except to the purchaser of all the material business
      assets and goodwill of the Licensee with respect to all the Licensed
      Products, who shall have agreed with Unilever in writing prior to such
      assignment or transfer to accept all of the Licensee's obligations under
      this Agreement with respect to the Licensed Products, and any such licence
      so transferred may thereafter continue to be used by the purchaser only in
      connection with the Licensee's business assets which are so purchased.

3.    PAYMENTS

3.1   In consideration of the licence granted in clause 2.1 hereof, the Licensee
      will pay to Unilever an initial non-returnable sum of [***] and provided
      that [***] will be fully credited until exhausted against royalty payments
      due under clause 3.3 made on and subsequent to the Effective Date until
      31st December 1999. No part of the fully creditable [***] will be credited
      against royalty payments due under clause 3.3 after 31st December 1999. In
      the event royalty payments due under clause 3.3 made on and subsequent to
      the Effective Date until 31st December 1999 do not amount to [***], the
      remaining part of the credit will be lost. The initial non-returnable sum
      of [***] will be paid by Licensee in [***] instalments of [***] by the
      following dates (the due dates):

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

            First instalment: within thirty (30) days from the Effective date
            Effective date
            Second Instalment: by 31 March 1999
            Third Instalment: by 30 June 1999
            Fourth Instalment: by 30 September 1999

3.2   In consideration of the licence option granted in clause 2.2 hereof, the
      Licensee will pay to Unilever a non-returnable sum of [***] per analyte
      upon exercise of the licence option, within thirty (30) days upon exercise
      of the licence option.

3.3   The licensee will pay to Unilever a royalty on Licensed Products and on
      Products Under Option at a rate of [***] of all Net Sales made by Licensee
      and Affiliates on and after the Effective Date.

3.4   Only one royalty shall be paid upon sale of any Licensed Product
      regardless of the number of claims or patents within the Patent rights
      that may be otherwise infringed by the Licensed Product or its use. In the
      event that a Patent Right is declared invalid in a country by a decision
      by a court of competent jurisdiction and final resort, or a decision by an
      inferior tribunal from which no appeal has or can be taken, Licensee's
      obligation to royalties with respect to this Patent Right in said country
      will terminate immediately.

4.    ACCOUNTING AND AUDIT

      4.1   Within [***] after the end of each Calendar Half-year for the
            remainder of the term of this Agreement, the Licensee shall furnish
            to Unilever at the address in clause 7.3 hereof, a written report
            certified as correct by the Licensee's chief executive officer or
            senior qualified accountant setting forth the number, name and type
            of all Licensed Product in each country of sale upon which the
            Licensee is obligated to pay royalties and the computation of the
            royalties payable with respect thereto, together with the remittance
            of the amount due. A report will be furnished to Unilever whether or
            not any sales have been made in that Calendar Half-year. Any
            payments of royalties which are sent more than [***] after the

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      end of the Calendar Half-year shall bear interest at [***] percent per
      annum from the date on which payment was due to the date on which payment
      is received by Unilever.

4.2   Fees and royalties shall be paid in Pounds sterling by cheque payable to
      Unilever PLC at the address in clause 7.3 hereof, or otherwise as Unilever
      shall direct. All currency translations from the currency of sale to
      Pounds sterling will be made based on the mid-rate of exchange published
      by the Financial Times (London Edition) on the last business day of the
      relevant Calendar Half-year for calculation of royalties due under clause
      3.3.

4.3   All royalty payments provided for under this Agreement shall be made to
      Unilever in full, provided however that in any event and to the extent
      that any royalty or other sum payable hereunder is subject to [***], the
      Licensee has the right to [***]. All payments due under this Agreement are
      [***] where applicable.

4.4   The Licensee shall keep accurate records in sufficient detail to enable
      royalties payable hereunder to be determined, and shall permit such
      records to be inspected once per year with reasonable notice. In the event
      Unilever does not request an inspection of the records within three years
      following a royalty report the Licensee may dispose of the records. Any
      inspection of records shall be made during reasonable business hours by a
      certified accountant reasonably acceptable to the Licensee and appointed
      by Unilever at its expense for this purpose, but only to the extent
      necessary to verify the amount of royalties payable. The accountant shall
      be required to execute a non-disclosure agreement with Licensee, prior to
      such inspection, which will enable the accountant to report to Unilever
      the amount of royalty due and payable. Any amount of royalty found to be
      underpaid shall be promptly remitted to Unilever together with any
      interest at a rate of [***] per annum, and any amount or royalty found to
      be overpaid shall be deductible from subsequent royalty remittances, and
      if the amount of royalty found to be underpaid shall exceed [***] of the
      royalty payment for the respective period, the Licensee shall pay to
      Unilever the cost of the inspection of the records by the certified
      Accountant.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

5.    APPLICABLE LAW

5.1   This Agreement shall be deemed to have been made in and shall be construed
      in accordance with the laws of England for all matters (other than scope
      and validity of the Patent Rights which shall be construed and governed in
      accordance with laws of the jurisdiction in which the Patent Rights have
      been granted) and the parties submit to the jurisdiction of the English
      Courts.

6.    TERMINATION

6.1   The Licensee may terminate the licence granted in this Agreement at any
      time upon ninety (90) days written notice subject to payment of royalties
      in respect of sales of all Licensed Product and Product Under Option until
      termination.

6.2   Upon material default by either Party in the performance of any obligation
      to be performed by the other Party other than the payment under Clause
      3.1, the other Party may give written notice specifying the thing or
      matter in default. Unless the default is cured within sixty (60) days
      following the giving of notice, the Party making notice may give further
      written notice to the other Party forthwith terminating the licence
      granted hereunder. If any payment under Clause 3.1 is not made by the date
      at which it is due (the due date), the licence granted maybe terminated by
      Unilever thirty (30) days after receipt of written notice by Licensee from
      Unilever.

6.3   Licensee shall be authorized to challenge any Patent right.

      6.3.1 In the event that Licensee challenges, directly or indirectly, any
      Patent Right outside the territory of the U.S.A., Unilever shall have the
      right to terminate the license under this Patent Right immediately in the
      country in which the Patent Right is challenged.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      6.3.2 In the event that Licensee challenges any Patent Right in the
      territory of the U.S.A., Licensee will still be obliged to continue paying
      the royalties due under this Patent Right until a decision by a court of
      competent jurisdiction and final resort, or a decision by an inferior
      tribunal from which no appeal has or can be taken, has been issued.

6.4   Unilever may terminate upon written notice the licence rights of Licensee
      forthwith if the Licensee shall be declared bankrupt or shall enter into
      liquidation or receivership or similar state.

6.5   Unilever may terminate the licence rights of the Licensee forthwith if the
      Licensee manufactures, uses or sells (or procures any third party so to
      do), any product which is covered by the Patent Rights in the country of
      such manufacture use or sale, other than a Licensed Product or Product
      Under Option on which royalty is paid pursuant to this Agreement.

6.6   Unilever can terminate the licence on a per analyte basis on thirty (30)
      days written notice if the Licensee makes no sales of the particular
      Licensed Product or if the royalties received by Unilever are less than;

      - [***] per analyte in the period starting from the Effective Date of the
      Agreement and ending on 31st December 1999

      - [***] within any period of 12 months starting 1st January 2000,

      - unless Licensee makes up the difference between royalties owed for that
      period and the minimum royalties due to Unilever for such period.

6.7   Unilever can terminate the licence on a per analyte basis on thirty days
      (30) written notice if the Licensee makes no sales or Product Under Option
      or if the royalties received by Unilever are less than [***] per analyte
      within any period of 12 months starting one year after exercise of the
      option for the particular Product Under Option, unless Licensee makes up
      the difference between royalties owed for that period and the minimum
      royalties due to Unilever for such period.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

6.8   Termination pursuant to clauses 6.1 to 6.7 hereof shall not relieve either
      party of any obligations accrued prior to the termination.

6.9   Unless sooner terminated as provided above, the licence rights granted
      hereunder shall continue until expiration of the last to expire of the
      patents within the Patent Rights.

7.    GENERAL PROVISIONS

7.1   This Agreement supersedes all previous oral and written agreements between
      the parties and is the only and entire understanding existing between the
      parties with respect to the subject matter of this Agreement. Any
      amendment thereto shall be in writing and signed by the parties.

7.2   The provisions of this Agreement shall be deemed separable, and if any
      part of this Agreement is rendered void, invalid, or unenforceable, such
      rendering shall not affect the validity or enforceability of the remainder
      of the Agreement unless the part or parts which are void, invalid or
      unenforceable shall substantially impair the value of the whole Agreement
      to either party.

7.3   All notices and reports shall be sent to the parties at the addresses
      shown below. Such notice or report shall be deemed received when sent
      addressed to the party at the address shown below by registered mail with
      correct postage affixed and by facsimile on the same date and confirmed by
      mail within 14 days. The addresses for notices and reports may be changed
      by timely written notice to the other party.

      For the Licensee:       Attention: Chief Executive Officer
                              Adeza Biomedical Corporation
                              1240 Elko Drive
                              Sunnyvale, California 94089
                              USA
                              FAX: 408 745 7074

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      For Unilever:           Attention: The Senior Agreements Advisor
                              UNILEVER PLC
                              Patent Department
                              Colworth House
                              Sharnbrook
                              Bedfordshire MK 44 1LQ
                              England
                              Fax: 01234 222 633

7.4   Unilever represents and warrants that they own directly or indirectly all
      right title and interest in and to the Patent Rights or are otherwise
      authorised to enter into this Agreement. Unilever expressly does not
      warrant the validity of any of the Patent Rights but is not aware of any
      ground for invalidity thereof. The Licensee will promptly inform Unilever
      of any apparent infringements of the Patent Rights which come to its
      notice, and the parties will on request discuss the action to be taken in
      that respect. It is Unilever's intention to use reasonable efforts to
      enforce the Patent Rights, but Unilever shall not be compelled to take
      Court action against third party infringers. Unilever will advise the
      Licensee every six months of the status of the Patent Rights.

7.5   Unilever expressly does not warrant that any Licensed Product or Product
      Under Option is free from infringement of any third party patent or other
      intellectual property rights. The Licensee accepts full responsibility for
      the manufacture use and sale of all Licensed Product and Product Under
      Option and Unilever shall not be liable to Licensee for the consequences
      of any such infringement of third party rights or other damages caused to
      any third party by such manufacture use or sale, and the Licensee shall
      hold harmless and indemnify Unilever from any and all judgements of any
      kind which arise from such manufacture, use and sale of Licensed Product
      and Product Under Option.

7.6   The Licensee shall not make any use of the Unilever name or any trademark
      of Unilever or of any company in the Unilever Group in connection with the

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      manufacture use or sale of Licensed Product or Product Under Option or
      otherwise without the prior written consent of Unilever.

7.7   No licence is hereby granted to the Licensee by implication, estoppel or
      otherwise under any letters patent or application thereof other than under
      the Patent Rights.

7.8   Failure by either party to enforce any provision of this Agreement shall
      not be construed as a waiver of such provision and shall not affect the
      validity of the Agreement or any part thereof or the right of that party
      to enforce any provision thereof.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in
duplicate originals.

UNILEVER PLC                              ADEZA

BY /s/                                    BY: /s/

TITLE: Alain Eric Phillippe               TITLE: President
       (Authorised Signatory)

UNILEVER NV

BY(1): /s/

TITLE: Alain Eric Phillippe
       (Authorised Signatory)

BY(2): /s/

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

TITLE: J. P. Van Gent
       (authorised signatory)

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

APPENDIX 1

a) Granted rights

COUNTRY                                                                   NUMBER
--------------------------------------------------------------------------------
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
- designated states under the European patent are: -
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

APPENDIX 1 (cont.)

b) Pending Rights

[***]
[***]
[***]
[***]
[***]
[***]

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

APPENDIX 2

(a)   [***]

(b)   [***]
          [***]
          [***]

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]